Categories: CancerNews

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET

PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083

Staff

Recent Posts

Dräger PSS® AirBoss SCBA Now Available for Purchase in North America

Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…

3 hours ago

Greenway Health® Named Most Improved Physician Practice Solution 2026 by KLAS Research

KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…

3 hours ago

Huckleberry Launches Berry: Specialized AI that Brings Family Context Front and Center

While AI booms, Berry delivers quiet confidence to parents by pairing each child's unique logged…

3 hours ago

AI Lab Goodfire Raises $150M at $1.25B Valuation to Design Models with Interpretability

SAN FRANCISCO, Feb. 5, 2026 /PRNewswire/ -- Today, Goodfire—the AI research lab using interpretability to…

3 hours ago

Nanorobotics Market worth $4.52 billion by 2032 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global nanorobotics market…

3 hours ago

Vidle.com and LaborEdge Announce Strategic Integration to Streamline Healthcare Staffing Recruitment

Integration Delivers Faster Hiring, Qualified Candidates, and Zero Posting Fees for Healthcare Staffing AgenciesDELRAY BEACH,…

3 hours ago